Rituximab in the treatment of diffuse large B-cell lymphomas
- 1 February 2002
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (1) , 30-35
- https://doi.org/10.1053/sonc.2002.30153
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Signaling events involved in anti-CD20-induced apoptosis of malignant human B cellsCancer Immunology, Immunotherapy, 2000
- Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+B-Cell Non-Hodgkin's LymphomaJournal of Clinical Oncology, 1999
- Monoclonal antibody-based therapies for hematologic malignancies.Journal of Clinical Oncology, 1998
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Anti‐B4‐blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myelomaBritish Journal of Haematology, 1998
- Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal AntibodiesBlood, 1998
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.Journal of Clinical Oncology, 1996
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphomaBlood, 1994